PubMed · 1980 · 25 citations · 0 references
MedicineOncologyPharmacologyChemotherapyClinical PharmacologyOncology PharmacotherapyDose EscalationHematologic Malignancy PharmacotherapyHematologic ToxicityHigh-dose ChemotherapyPediatric LeukemiasToxicity ManagementAcute Leukemia ChemotherapyAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentChemotherapy-related ToxicityClinical RemissionHigh-dose Chemotherapy AdministrationRelapsed Acute Lymphoblastic LeukemiaRelapsed Leukemia
Thirteen patients with relapsed acute leukemia, 12 adults with acute nonlymphocytic leukemia, and one child with acute lymphoblastic leukemia were treated with VP 16-213, an epipodophyllotoxin analog, at a dose of 200-300 mg/m2/day X5 as a 2-hour intravenous infusion. Only four patients achieved bone marrow aplasia and three regenerated with leukemic cells. The fourth patient achieved a partial remission for 4 weeks. Toxicities included myelosuppression (WBC nadir 500/microliter), nausea and vomiting (70% of courses), mucositis (23%), esophagitis (12%), which contributed to death in one patient, hypotension (12%), and transient liver function abnormalities (12%). It is concluded that increasing the dose of VP 16-213 as employed in this study did not increase the therapeutic activity of VP 16-213 for the treatment of relapsed leukemia but did increase the risk of toxicity.